Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERBIOTAX: Cetuximab Plus/Minus Paclitaxel in Recurrent/Metastatic SCCHN
NCT06856213Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Oct 2028
- Modality
- Cytokines & Interferons, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Paclitaxel Micelles for Injection in squamous cell carcinoma of the head and neck (HNSCC) (2 arms). Primary endpoint: Objective Response Rate at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT06856213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06856213.